Zum Inhalt

Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

  • 28.02.2024
  • original report
Erschienen in:

Summary

Background

The purpose of this study was to assess the correlation between textural features from 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) or computed tomography (CT) and EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.

Methods

In all, 71 patients who were diagnosed with stage IV adenocarcinoma lung cancer between April 2014 and August 2018 were included in this study. 18F-FDG-PET/CT scanning and EGFR mutation tests were performed before targeted molecular therapy. Textural features were extracted from manually segmented volumes of tumors, and highly dependent features were excluded. Multivariate logistic regression analysis was used to establish predictive models for detection of EGFR mutations. Receiver operating characteristic (ROC) curves were applied to evaluate areas under the curves (AUCs) of each model.

Results

Of the 71 patients, 39 (54.9%) were EGFR mutation and 32 (45.1%) showed wild-type. EGFR mutation status was significantly associated with female sex (P = 0.026). In multivariate analysis, three PET (co-occurrence contrast, intensity-size-zone low-intensity large-zone emphasis, and texture spectrum max spectrum) and two CT quantitative features (intensity-size-zone high-intensity zone emphasis and normalized co-occurrence second angular moment) were independent predictors of EGFR mutation status. The predictive model generated from combined clinical and textural features showed a better predictive value than the model from textural features alone (AUC 0.897 vs 0.864).

Conclusions

Textural features combined with clinical features could establish a model for improving the predicting power of EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.
Titel
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
Verfasst von
Changbin Wang
Ran Zhang
Xiaorong Sun
Ligang Xing
Publikationsdatum
28.02.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00961-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.